

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1 α and MITF

Rizwan Haq,^{1,2} Jonathan Shoag,⁴ Pedro Andreu-Perez,² Satoru Yokoyama,^{2,5} Hannah Edelman,² Glenn C. Rowe,⁴ Dennie T. Frederick,³ Aeron D. Hurley,⁶ Abhinav Nellore,⁷ Andrew L. Kung,⁸ Jennifer A. Wargo,³ Jun S. Song,⁷ David E. Fisher,^{1,2,9,*} Zolt Arany,^{4,9,*} and Hans R. Widlund^{6,9,*}

¹Massachusetts General Hospital Cancer Center

²Department of Dermatology, Cutaneous Biology Research Center

³Department of Surgery

Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

⁴Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA 02116, USA

⁵Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan

⁶Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA

⁷Department of Epidemiology and Biostatistics, Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143-0794, USA

⁸Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA

⁹These authors contributed equally to this work

*Correspondence: dfisher3@partners.org (D.E.F.), zarany@bidmc.harvard.edu (Z.A.), hwidlund@bics.bwh.harvard.edu (H.R.W.)

<http://dx.doi.org/10.1016/j.ccr.2013.02.003>

SUMMARY

Activating mutations in *BRAF* are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1 α . We further show that a target of BRAF, the melanocyte lineage factor MITF, directly regulates the expression of PGC1 α . Melanomas with activation of the BRAF/MAPK pathway have suppressed levels of *MITF* and *PGC1 α* and decreased oxidative metabolism. Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors.

INTRODUCTION

Activating mutations in the BRAF protein kinase are the most common genetic alterations in melanoma, found in ~50% of tumors (Davies et al., 2002; Curtin et al., 2005). The most frequent BRAF mutation is the substitution of valine at position 600 by glutamic acid (BRAF V600E) that results in the constitutive activation of its serine/threonine kinase activity and sustained activation of the mitogen-activated protein kinase (MAPK) signal transduction pathway (Davies et al., 2002; Wan et al., 2004). BRAF directly phosphorylates the dual-specificity kinases MEK1 and MEK2, which in turn phosphorylate and acti-

vate the MAPKs, ERK1 and ERK2. BRAF has been shown by overexpression and knockdown experiments to be a critical mediator of melanomagenesis. In mice, activation of BRAF in combination with deletion of the tumor suppressor genes *PTEN* or *INK4A* leads to melanoma with complete penetrance (Dankort et al., 2009; Dhomen et al., 2009). Conversely, treatment of BRAF mutant melanomas in vitro with chemical inhibitors of BRAF or MEK1/MEK2 promotes cell-cycle arrest and apoptosis (Hingorani et al., 2003; Karasarides et al., 2004; Hofflich et al., 2006; Wellbrock et al., 2008). Moreover, the BRAF inhibitor vemurafenib (PLX4032) leads to tumor regression and improved overall survival in patients whose melanomas have

Significance

BRAF mutations are the most common genetic aberrations in melanoma, but the mechanisms by which they promote oncogenesis are poorly understood. Here, we show that activated BRAF promotes metabolic reprogramming by suppression of oxidative phosphorylation through the actions of the melanocyte lineage factor *MITF* and the mitochondrial master regulator PGC1 α . BRAF inhibitors, which transiently suppress melanoma growth in vitro and in patients, induce PGC1 α and oxidative phosphorylation. This addition to oxidative phosphorylation in melanomas treated with BRAF-targeted therapy therefore suggests that mitochondrial inhibitors should be evaluated in combination with BRAF pathway inhibitors in vivo.

the BRAF(V600E) mutation, leading to its approval as a treatment for patients with metastatic melanoma (Flaherty et al., 2010; Chapman et al., 2011; Sosman et al., 2012). Despite the promise and dramatic initial effects of BRAF inhibitors in the clinic, patients eventually relapse within a few months, suggesting that combination therapies may be needed to overcome intrinsic or acquired resistance (Gray-Schopfer et al., 2007; Poulikakos and Rosen, 2011).

Although melanomas with BRAF mutations have constitutively active growth signals, how they sustain their growth in the setting of nutrient scarcity is not well understood. In 1930, Otto Warburg proposed that cancer cells have a high rate of glycolysis as compared to oxidative metabolism even under conditions of high oxygen, a phenomenon known as the Warburg effect (Warburg, 1956; Vander Heiden et al., 2009). Oxidative phosphorylation depends on the ability of functionally intact mitochondria to metabolize oxygen, whereas glycolysis can occur independently of mitochondria. Warburg theorized that this metabolic switch facilitated the uptake and incorporation of nutrients that were required for cellular proliferation. Although poorly understood in melanoma, the molecular mechanisms of metabolic reprogramming in cancer have been described in other tumor types. TP53-deficient tumor cells have diminished levels of the genes *TIGAR* and *SCO2*, which regulate glycolysis and assembly of the mitochondrial cytochrome c oxidase complex, respectively (Bensaad et al., 2006; Matoba et al., 2006). Similarly, the dysregulation of the proto-oncogene *MYC* leads to profound effects on tumor metabolism through multiple mechanisms (reviewed in Dang, 2012).

These observations have raised the possibility of targeting key metabolic pathways to inhibit cancer growth. Yun et al. demonstrated that several colorectal cancers with KRAS or BRAF mutations have increased glucose uptake and glycolysis and survived better in low-glucose conditions compared to nonmutated cell lines (Yun et al., 2009). Suppression of glycolysis with 3-bromopyruvate (a nonactive intermediary in the glycolysis pathway) reactivates mitochondrial metabolism in tumor cells, induces their selective killing, and suppresses cancer growth. Similarly, suppression of glycolysis by inhibiting conversion of pyruvate to lactate enhances oxidative phosphorylation and suppressed the growth of breast cancer cell lines (Fantin et al., 2006; Bonnet et al., 2007). Thus, whereas metabolic reprogramming is commonly found in cancer, the mechanism and details of metabolic alterations in melanoma are unknown.

Mitochondrial biogenesis and oxidative phosphorylation are well known to be controlled by the members of the peroxisome proliferator-activated receptor γ coactivator 1 (PGC-1) family of transcriptional coactivators (PGC1 α , PGC1 β , PPRC1) (Lin et al., 2005a; Finck and Kelly, 2006; Handschin, 2009; Leone and Kelly, 2011). The best-studied PGC-1 family member, PGC1 α , potently activates coordinated gene expression programs by interacting with transcription factors, the basal transcriptional machinery, histone-modifying enzymes, and the RNA-splicing machinery. PGC1 α drives mitochondrial biogenesis in multiple contexts, including brown and white adipocytes (Wu et al., 1999; Uldry et al., 2006), skeletal muscle (Lin et al., 2002), and the heart (Lehman et al., 2000). PGC1 α mRNA expression is sensitive to numerous signaling inputs that have been implicated in cancer biology (Herzig et al., 2001; Yoon

et al., 2001; Chinsomboon et al., 2009; Arany et al., 2008). PGC1 β shares significant sequence homology and functional overlap with PGC1 α , including the activation of mitochondrial biogenesis and oxidative phosphorylation, but also has several distinct functions in different tissues (Lin et al., 2005b; Uldry et al., 2006; Wolfrum and Stoffel, 2006). The regulation of PGC1 β has been less extensively studied. Although little is known about the role of the PGC-1s in melanoma, they have recently been implicated in metabolic shifts in breast cancer cells and colon cancers (Eichner et al., 2010; Bhalla et al., 2011; Sahin et al., 2011; Wang and Moraes, 2011; Girmun, 2012; Klimcakova et al., 2012). Here, we comprehensively evaluate the effect of BRAF pathway activation on metabolic gene expression and function in melanoma.

RESULTS

BRAF Regulates Metabolic Reprogramming of Melanomas

The mechanisms by which oncogenic BRAF promotes oncogenesis are incompletely understood. Gene set enrichment analysis (GSEA) provides a bioinformatics approach to identify gene signatures among microarray data sets that are induced or suppressed as small coordinated changes in individual genes (Mootha et al., 2003). In order to identify gene expression programs altered by oncogenic BRAF, we evaluated previously published gene expression profiles of BRAF mutant melanomas treated with the BRAF inhibitor vemurafenib (Joseph et al., 2010). As shown in Figure 1A, treatment of BRAF mutant melanomas with vemurafenib resulted in significant increases in the expression of the citric acid cycle gene set (Figure 1A) as well as multiple oxidative phosphorylation and ATP synthesis gene sets (Table S1 available online). Similarly, melanoma cells treated with PD0325901, a preclinical inhibitor of the MEK1/MEK2 protein kinases (Pratilas et al., 2009; Joseph et al., 2010), also exhibited a trend toward induction of the citric acid cycle and oxidative phosphorylation gene sets (Table S2). In contrast, we did not find enrichment of oxidative phosphorylation, or citric acid cycle gene sets in BRAF mutant nonmelanomas treated with PD0325901 (Table S3). We validated the effects of vemurafenib on OXPHOS gene expression in three melanoma cell lines by quantitative PCR (qPCR) (Figures S1A–S1C).

To directly evaluate the effect of BRAF inhibition on oxidative phosphorylation and mitochondrial number and function, we treated melanoma cell lines with PLX4720, a preclinical analog of vemurafenib (Tsai et al., 2008). PLX4720 increased the mitochondrial density of two BRAF mutant melanomas as detected by MitoTracker Green, which localizes to mitochondria independent of membrane potential. PLX4720 did not affect the mitochondrial density of MeWo cells that are BRAF wild-type (Figure 1B). PLX4720 also induced MitoTracker Red fluorescence, a measure of mitochondrial activity and mass (Figure 1C), and increased the production of mitochondrial oxidative stress measured by the MitoSOX fluorescence assay (Figure 1D). To confirm these findings, we also evaluated mitochondrial number by electron microscopy after treatment of the BRAF mutant melanoma cell line UACC62 with PLX4720. As seen in Figures 1E and S1D, inhibition of BRAF led to a significant increase in the number of mitochondria per cell.




Figure 1. BRAF Inhibitors Induce Mitochondrial Biogenesis and Oxidative Metabolism

(A) GSEA plot of melanoma cells treated with vemurafenib showing the most significantly changed gene set. FDR, false-discovery rate; ES, enrichment score. (B) MitoTracker Green fluorescence of BRAF mutant (UACC-62 and UACC-257) or BRAF wild-type (MeWo) melanoma cell lines treated with PLX4720 (1 μ M, 72 hr) and subjected to analysis by flow cytometry.

(C and D) MitoTracker Red fluorescence (C) or MitoSOX fluorescence (D) of UACC-62 cells treated with PLX4720.

(E) Electron micrographs of UACC-62 cells treated with PLX4720 or vehicle control. Representative photographs of cells at 22,000 \times (upper panel) or 44,000 \times (lower panel) are shown. Arrowhead indicates a representative mitochondrion.

(F) Lactate levels in media conditioned from the indicated cell lines treated with PLX4720 or vehicle control for 16 hr.

(G) Cells in (F) were concomitantly evaluated for ERK activity by western blotting using phospho-ERK antibodies.

Error bars represent SEM of at least three independent replicates. ***p < 0.001; **p < 0.01. ns, not significant.

See also Tables S1–S3 and Figure S1.

The conversion of glucose to lactate, as noted by Warburg, can be due to the shunting of pyruvate away from oxidative phosphorylation (Vander Heiden et al., 2009). In line with our findings above, PLX4720 reduced lactate levels in all BRAF mutant melanomas evaluated (Figure 1F). Lactate levels did not change upon treatment of a melanoma cell line that does not contain the BRAF mutation, consistent with the inability of PLX4720 to suppress ERK signaling in these cells (Figure 1G). Collectively, our data suggest that BRAF suppresses oxidative phosphorylation gene expression and mitochondrial density in melanoma.

BRAF and MAPK Activation Suppresses PGC1 α

Because oxidative phosphorylation depends on mitochondrial number and activity, their alteration may contribute to altered tumor metabolism. Candidate pathways, which physiologically regulate mitochondrial content and function, include the mitochondrial transcription factors A (TFAM) and B (TFB1M, TFB2M), nuclear respiratory factor 1 (NRF1), GA binding proteins (GABPA, GABPB2), peroxisome proliferator-activated receptors

(PPAR α , PPAR β), PPAR- γ coactivators (PGC1 α , PGC1 β), and PGC1-related coactivator 1 (PPRC1) (reviewed in Kelly and Scarpulla, 2004).

We observed that BRAF(V600E) expression suppressed PGC1 α , a well-known regulator of mitochondrial metabolism in the microarray data sets above. To validate these observations, we treated a series of BRAF mutant melanomas and nonmelanoma cell lines with PLX4720 and evaluated the effect on PGC1 α mRNA (Figure 2A). In all melanomas with BRAF mutations, PLX4720 induced 3- to 14-fold increases in PGC1 α mRNA. We did not observe any changes in the expression of PGC1 α in a BRAF wild-type MeWo cell line treated with PLX4720. Surprisingly, we did not observe any effects of PLX4720 on PGC1 α expression in two BRAF mutant colon cancer cell lines, despite suppression of ERK phosphorylation similar to that seen in melanomas (Figure 2B). We did not observe any change in PGC1 β mRNA upon treatment with PLX4720 or any effects in a BRAF wild-type melanoma over 24 hr (Figures S2A and S2B). These data suggested that there




Figure 2. BRAF Inhibitors Induce PGC1 α Expression

(A and B) PGC1 α mRNA (A) and phospho-ERK levels (B) in melanoma or colon cancer cells treated with PLX4720 (1 μ M) for 24 hr.

(C and D) PGC1 α mRNA (C) and ERK activity (D) in melanoma cells treated with the MEK inhibitor PD0325901 (10 nM) for 24 hr.

(E) Microarray analysis (GSE10086) of PGC1 α mRNA in cell lines treated with 10 nM PD0325901 for 24 hr.

(F) Comparison of PGC1 α mRNA with MITF, melanocytic markers, and MITF targets in 105 melanoma cell cultures (Hoek et al., 2006). Pearson correlation coefficient is shown below each gene.

Error bars represent SEM of at least three independent replicates. ****p < 0.0001; ***p < 0.001; *p < 0.01.

See also Figure S2.

might be lineage-specific differences in the regulation of PGC1 α by BRAF. To validate our findings using a structurally unrelated small molecule, we treated several melanoma cell lines with the MEK inhibitor PD0325901. Induction of PGC1 α mRNA (Figure 2C) and suppression of ERK phosphorylation (Figure 2D)

were seen in all cell lines tested including the BRAF wild-type melanoma MeWo, suggesting that the BRAF/MEK/ERK pathway regulates PGC1 α expression in melanoma cells. These results were also confirmed with additional NRAS mutant melanoma cell lines treated with a MEK1/MEK2 inhibitor (Figures S2C and S2D). Finally, we evaluated the expression of PGC1 α in an independent data set of A375 melanoma cells selected for resistance to BRAF inhibitors (Greger et al., 2012). We observed that PGC1 α expression was 10-fold lower in cells that had acquired resistance to BRAF inhibitors (Figure S2E), likely reflecting their higher demonstrated basal MAPK activity.

We also interrogated a publicly available microarray of 12 breast, lung, colon, and melanoma cell lines treated with PD0325901 (Joseph et al., 2010). Suppression of MEK only affected PGC1 α mRNA in melanoma cell lines (Figure 2E; p < 0.0001), suggesting that the regulation of PGC1 α mRNA by the BRAF/MEK/ERK pathway is unique to the melanocytic lineage. Consistent with our results, we found that PGC1 α expression was significantly correlated with melanocyte-specific antigen expression in a data set comprising of 105 melanoma cell cultures (Hoek et al., 2006) (Figure 2F).

PGC1 α mRNA Is Directly Regulated by the MITF Transcription Factor

To elucidate how BRAF may regulate PGC1 α , we compared the expression pattern of all human transcription factors to PGC1 α in a large microarray data set of short-term melanoma cultures (Lin et al., 2008). Among the transcription factors whose expression most closely paralleled PGC1 α , we observed that both transcription factor EB (TFEB) and the microphthalmia-associated transcription factor (MITF) were significantly associated with PGC1 α expression (q < 0.001) (Figure 3A). Both TFEB and MITF are members of a four-member family of distinctly encoded transcription factors (TFEB, TFEC, TFE3, and MITF) that share a common structure, binding recognition sequence, and function (Haq and Fisher, 2011). Whereas TFEB, TFEC, and TFE3 are ubiquitously expressed, MITF is largely restricted to the melanocytic lineage. The correlation of PGC1 α to MITF was therefore interesting in light of our data suggesting BRAF regulation of PGC1 α in melanoma, but not in other lineages (see Figures 2A and 2E). MITF expression correlated with PGC1 α as shown above (see Figure 2F).

We therefore evaluated the requirement of TFE3, TFEB, and MITF for the expression of PGC1 α by siRNA. In both M14 melanoma cells and primary human melanocytes, suppression of MITF but not TFEB or TFE3 (Figures 3B and S3A) led to a significant suppression of PGC1 α (Figures 3C and S3B) despite similar knockdown efficiency. We were unable to reliably detect TFEC expression in the cell lines tested (data not shown). MITF suppression in two other melanoma lines also significantly reduced PGC1 α expression (Figure S3C), which was validated using two independent shRNAs (Figure S3D).

In silico analysis of the PGC1 α promoter identified three putative MITF recognition sequences ("E boxes"), which were conserved among mammalian species. One E box was located approximately 420 bp upstream of the transcriptional start site, whereas a proximal E box was located within 20 bp of the start site (Figure 3D). Another E box was located approximately 10 kb upstream of these sequences, in the promoter sequences of an




Figure 3. PGC1 α Is Regulated by MITF in the Melanocytic Lineage

(A) Top ten transcription factors correlated to PGC1 α mRNA in Lin et al. (2008). * $p < 0.05$.

(B and C) Requirement of MIT family members for PGC1 α expression in M14 melanoma cells. Knockdown of each family member is shown in (B).

(D) Structure of PGC1 α promoter in mammalian species showing the location of alternative (alt) exon 1 and exon 1. Also depicted are the locations of E box 1 and E box 2 and primers used for ChIP.

(E) ChIP of indicated genomic region with anti-MITF, or rabbit IgG in primary melanocytes. Precipitated DNA was amplified using primers depicted in (D). *** $p < 0.001$ compared to rabbit IgG control.

(legend continued on next page)

alternative exon 1 (PGC1 α -alt) (Miura et al., 2008; Chinsomboon et al., 2009). To evaluate if MITF could directly bind to the PGC1 α promoter, we performed chromatin immunoprecipitation (ChIP) using primers located either near alternative exon 1 or exon 1 (see Figure 3D). As shown in Figure 3E, MITF was found to bind to the proximal PGC1 α promoter but not to the PGC1 α -alt promoter in primary melanocytes. Due to limits in the resolution of this assay, we were unable to distinguish if MITF binds to E box 1, E box 2, or both. We therefore utilized a PGC1 α promoter cloned upstream of the luciferase reporter gene (Handschin et al., 2003) and mutated each E box by site-directed mutagenesis (Figure 3F). MITF overexpression (Figure 3F) or treatment with PLX4720 (Figure 3G) led to the induction of the wild-type promoter, whereas mutation of either of the two E boxes significantly inhibited this response. Collectively, these data indicate that MITF binds and directly regulates the PGC1 α gene in the melanocyte lineage. To evaluate if BRAF regulates PGC1 α via MITF, we suppressed MITF using siRNA, then used PLX4720 to inhibit BRAF(V600E) activity. As shown in Figure 3H, treatment with PLX4720 strongly induced PGC1 α mRNA in M14 cells and \sim 3-fold in UACC62 cells, and this induction was absent in cells in which MITF was knocked down by siRNA. These data indicate that BRAF regulates PGC1 α via MITF.

BRAF Negatively Regulates MITF Activity

The relationship between BRAF and MITF is poorly understood because oncogenic BRAF and the ERK pathway promote MITF activation but also lead to its degradation (Hemesath et al., 1998; Wu et al., 2000; Wellbrock and Marais, 2005; Wellbrock et al., 2008; Boni et al., 2010). We therefore examined the consequences of ectopic BRAF(V600E) expression in immortalized melanocytes. Introduction of oncogenic BRAF was associated with decreased levels of M-MITF protein (the melanocyte-specific isoform), but not other isoforms (Figure 4A). Conversely, the MEK inhibitor PD0325901 induced the expression of TRPM1 and other direct targets of MITF in published microarrays (Figure 4B) and by qPCR (Figure 4C). As shown in Figure 4D, knockdown of MITF blocked induction of TRPM1, suggesting these effects were dependent on MITF. In line with these findings, we observed that treatment of UACC-257 cells with PLX4720 for 72 hr led to increased pigmentation, reflecting MITF's essential role in melanin synthesis and pigmentation (Figure 4E).

We were unable to detect a correlation between BRAF mutation status and PGC1 α or MITF expression in short-term cultures. Given the prevalence of MAPK pathway mutations other than BRAF(V600E) in melanoma, we evaluated the expression of PGC1 α and MITF in melanomas with either high or low expression of a MAPK activation gene signature. Both MITF (t test, $p = 1.4 \times 10^{-14}$) and PGC1 α (t test, $p = 1.34 \times 10^{-5}$) expression inversely correlated with MAPK activity (Figure 4F). Collectively, these data suggest that BRAF/MAPK inhibition leads to

activation of MITF mRNA and protein and that this induction leads to induction of MITF targets including PGC1 α .

To evaluate if BRAF suppression alters the BRAF/MITF/PGC1 α pathway described here in vivo, we obtained serial biopsies from 11 patients prior to treatment with BRAF/MEK inhibitors and 10–14 days after beginning treatment (patient characteristics described in Straussman et al., 2012). Of eight samples that had detectable phosphorylated ERK at baseline (Figure 5A), all had induction of PGC1 α upon treatment (Figure 5B). Comparison to separately analyzed levels of M-MITF induction following BRAF-targeted therapy revealed a significant correlation to PGC1 α induction within these patient-derived specimens (J.A.W., unpublished data). Together, these data indicate that the OXPHOS adaptive response described here exists in vivo.

MITF Promotes Expression of Oxidative Phosphorylation Genes

Up to 30% of melanomas harbor genomic amplifications of MITF (Garraway et al., 2005), and MITF is required for the survival of at least a subset of melanomas. Activating point mutations have also been identified in melanoma (Bertolotto et al., 2011; Yokoyama et al., 2011). These data have led to the designation of MITF as a lineage-specific melanoma oncogene (Garraway et al., 2005). Comprehensive expression profiling approaches have identified roles for MITF in promoting cell growth and survival, organelle biogenesis, the oxidative stress response, and miRNA regulation (Vachtenheim and Borovanský, 2010; Haq and Fisher, 2011). However, a role for MITF in regulating metabolism has not been previously described. We therefore tested if MITF expression correlated with oxidative phosphorylation by classifying melanomas into two groups based on a previously defined oxidative phosphorylation signature. As seen in Figure 6A, melanomas with high MITF expression had significantly higher oxidative phosphorylation gene expression ($p = 5.51 \times 10^{-5}$). Similarly, MITF expression correlated with PGC1 α -regulated gene expression ($p = 1.42 \times 10^{-15}$).

To evaluate if MITF was sufficient to drive oxidative phosphorylation in melanoma, we evaluated two matched human cell lines derived from primary melanocytes. These two cell lines (termed pmel*+BRAF(V600E) and pmel*+BRAF(V600E)+MITF) are derived from primary normal human melanocytes by immortalization using telomerase, with a constitutively active allele of cyclin-dependent kinase 4 and dominant-negative p53 (Garraway et al., 2005). These cells are therefore isogenic with the exception of the expression of MITF. Consistent with published reports by Garraway et al. (2005) and our results above, expression of M-MITF protein was undetectable in pmel*+BRAF(V600E) cells but strongly expressed in the derived MITF-expressing cells, which correlated with PGC1 α expression (Figure 6B). BRAF(V600E) cells expressing MITF were able to form tumors in immunocompromised mice, whereas control cells were not

(F and G) Activity of PGC1 α promoters upstream of the luciferase gene mutated as depicted in response to transfection of MITF (F) or treatment with PLX4720 (G). Gray boxes indicate the location of E boxes.

(H) Expression of PGC1 α following knockdown of MITF (48 hr) and treatment with PLX4720 (1 μ M, 24 hr) in M14 cells (left) or UACC-62 cells (right).

Error bars represent SEM of at least three independent replicates. ** $p < 0.01$; *** $p < 0.001$.

See also Figure S3.




Figure 4. BRAF Suppresses MITF Expression and Activity

(A) Levels of M-MITF (arrows) and phosphorylated ERK in pmel* and pmel* BRAF(V600E).

(B) Effects of MEK inhibitor PD325901 on MITF mRNA and MITF targets by published microarray (Pratils et al., 2009).

(C) Response of MITF and MITF targets to PLX4720 in UACC-257 cells by qPCR. * $p < 0.01$; *** $p < 0.001$ relative to DMSO control.

(D) Effect of MITF suppression on induction of MITF-target TRPM1 by PLX4720. ** $p < 0.01$; *** $p < 0.001$ relative to siControl. Error bars represent SEM of at least three independent replicates.

(E) Consequence of PLX4720 (72 hr) on UACC-257 pigmentation. Equal number of cells were pelleted by centrifugation.

(F) Box plots showing expression of MITF (left) and PGC1 α in melanoma cells with high or low MAPK activation from 88 short-term melanoma cultures (Lin et al., 2008).

To evaluate the metabolic consequence of MITF overexpression directly, we evaluated glycolysis and oxidative phosphorylation in the isogenic cells. Overexpression of MITF did not increase glucose uptake (Figure 6D) but, strikingly decreased lactate production (Figure 6E) and increased oxygen consumption (Figure 6F), consistent with enhanced mitochondrial metabolism. Conversely, BRAF(V600E) cells had elevated sensitivity to knockdown of pyruvate kinase (muscle isoform), the final step in the glycolysis pathway, compared to isogenic cells expressing MITF (Figure S4D), despite similar degrees of knockdown efficiency in the two cell lines (Figure S4E).

To further validate these findings in patient-derived melanomas, we suppressed MITF by shRNA and performed gene expression profiling. We identified several genes involved in oxidative phosphorylation that were dependent on MITF (Figure S4F), consistent with the aforementioned gene expression data.

With the exception of PGC1 α , whose promoter was found to be directly bound by MITF, oxidative phosphorylation genes were not bound by MITF but have been identified as PGC1 α targets in other cell lineages (Mootha et al., 2003). We conclude that MITF overexpression is sufficient and necessary to drive oxidative metabolism and metabolic reprogramming in the melanocyte lineage.

BRAF Inhibition Leads to Bioenergetic Adaptation by Induction of MITF and PGC1 α

Collectively, the data above support the notion that BRAF inhibition endangers ATP production, which is rescued by concomitant induction of MITF, PGC1 α , and oxidative metabolism. To

(Figure 6C), paralleling previous data from soft agar growth (Garraway et al., 2005). Similar to our findings with BRAF inhibition, GSEA of microarray data identified a highly significant induction of the oxidative phosphorylation gene set in MITF-expressing cells compared to control cells ($q = 0.0$, $p < 5 \times 10^{-4}$; see Figure 6C). We found that a large majority of the oxidative phosphorylation gene set was induced by MITF overexpression (Figure S4A), consistent with the ability of PGC1 α to strongly upregulate many oxidative phosphorylation genes (Mootha et al., 2003). We validated the expression of differentially expressed genes (chosen to represent different mitochondrial processes) by qPCR (Figure S4B) and found significant increases in several oxidative phosphorylation genes. Similarly, expression of the oxidative phosphorylation genes was suppressed by oncogenic BRAF (Figure S4C).




Figure 5. Validation of Induction of PGC1 α Pathway In Vivo following BRAF Inhibition

(A) Expression of phospho-ERK in eight matched patient biopsies prior or during (10–14 days) treatment with BRAF/MEK inhibitors. Scale bar represents 100 μ m.

(B) Expression of PGC1 α mRNA prior and during treatment with BRAF/MEK inhibitors. Error bars represent SEM of at least three technical replicates.

experimentally test this hypothesis, we evaluated the response of the isogenic cell lines expressing BRAF(V600E) with or without M-MITF overexpression to PLX4032. Inhibition of BRAF resulted in a 42% drop in ATP in BRAF(V600E) parental cells, whereas the magnitude of this drop was reduced in MITF-overexpressing cells (Figure 6G), despite similar basal ATP concentrations. Consistent with MITF effects on oxidative metabolism, BRAF(V600E)+MITF cells were significantly more sensitive to the mitochondrial uncoupler 2,4-dinitrophenol (DNP; Figure 7A).

We also evaluated the magnitude of bioenergetic compensation in eight patient-derived melanoma cell lines. As shown in Figure 7B, in all cases, there was induction of PGC1 α following vemurafenib treatment, which varied in magnitude by cell line. We also measured ATP levels before and after treatment with vemurafenib, and we observed a significant correlation between induction of PGC1 α and ATP levels in BRAF mutant cells ($R = 0.72$, $p = 0.03$; Figure 7C). Strikingly, the two lines with highest ATP levels following BRAF inhibition are the ones with the strongest induction of PGC1 α . These data suggest that the metabolic switch to “normal” varies in magnitude among different melanoma cell lines and suggest that the inhibition of BRAF leads to a bioenergetic crisis that can be variably rescued by induction of the MITF/PGC1 α pathway.

We next asked whether oxidative metabolism could be exploited to inhibit the growth of melanoma cells. We compared the sensitivity of melanoma cells to primary melanocytes (Figure S5). All melanoma cells were more sensitive to DNP than primary melanocytes, except A375P. Treatment of UACC257 cells, but not A375P cells, with DNP led to a decrease in ATP and increases in lactate, consistent with inhibition of OXPHOS (Figures 7D and 7E). To validate the effects of mitochondrial

inhibitors on tumor growth in vivo, we treated animals bearing tumor xenografts of A375P and UACC257 melanoma cells with DNP. Consistent with the in vitro data, we found that longitudinal treatment of UACC257 xenografts profoundly inhibited tumor growth, similar to the effects of PLX4032 (Figure 7F), whereas A375P cells were insensitive to 2,4-DNP (Figure 7G).

Melanomas Treated with BRAF Inhibitors Are Addicted to Oxidative Metabolism

Our observations that BRAF and MITF regulate PGC1 α expression prompted us to evaluate if oxidative metabolism affected response to BRAF inhibitors. We observed that high levels of PGC1 α were associated with poorer prognosis in patients with stage III melanoma (Figure S6A) (Bogunovic et al., 2009). To this end, forced expression of PGC1 α protected cells from PLX4720, as demonstrated using three cell lines that expressed low levels of PGC1 α (Figures 8A–8C). Because our data suggest that BRAF regulates PGC1 α and oxidative phosphorylation, we evaluated the effects of inhibitors of oxidative phosphorylation in combination with BRAF inhibitors. In addition, the cells were found to be relatively insensitive to the mitochondrial uncoupler CCCP, but addition of PLX4720 enhanced the cytotoxicity of this drug (Figure 8D). Melanoma cells treated with 2,4-DNP, or oligomycin A, which inhibits oxidative phosphorylation through different mechanisms, additively enhanced the efficacy of PLX4720 in vitro (Figure 8E). We also found similar data using rotenone and the complex II inhibitor, TTFA (Figures S6B and S6C). Together, the data indicate that induction of oxidative phosphorylation in response to BRAF inhibition limits the therapeutic efficacy of BRAF inhibitors.

DISCUSSION

Previous studies have suggested a role for BRAF signaling in the regulation of tumor metabolism. Clinically, patients with BRAF mutant melanomas have higher levels of serum lactate consistent with diminished oxidative phosphorylation (Board et al., 2009). In addition, BRAF mutant melanomas have an order of magnitude increased uptake of glucose compared to normal tissues in vivo as assessed by functional imaging (Bollag et al., 2010). However, the mechanism by which BRAF regulates metabolism in melanoma is poorly understood. This study identifies a pathway by which the oncogenic BRAF pathway regulates energy metabolism in melanoma. Our findings show that BRAF activation is associated with diminished oxidative enzymes, diminished mitochondrial number and function, and increased production of lactate. This metabolic reprogramming triggered by BRAF(V600E) is accompanied by a suppression of MITF and PGC1 α , a major regulator of mitochondrial biogenesis and function.

We identify the melanocyte master regulator MITF as a direct and essential mediator of BRAF-regulated PGC1 α transcription. Consistent with the restricted expression of MITF to the melanocyte lineage, the ERK pathway does not appear to regulate PGC1 α transcription in BRAF mutant cancers that lack MITF expression. The MITF-PGC1 connection thus explains the lineage-specific effects of BRAF activation and inhibition.

Although BRAF inhibitors can suppress glycolysis and induce oxidative phosphorylation, we found that MITF only regulates mitochondrial respiration. Consistent with this, MITF and PGC1 α expression correlate with oxidative phosphorylation genes in




Figure 6. MITF Regulates Oxidative Phosphorylation

(A) Box plots depicting MITF expression in melanomas with high expression of a PGC1 α -target gene set (bottom) or oxidative phosphorylation gene set (top).

(B) Western blotting showing expression of MITF and PGC1 α in pmel⁺ BRAF(V600E) with and without MITF overexpression.

(C) Schema showing isogenic system evaluating the effect of MITF overexpression in BRAF(V600E) melanoma cells. The tumorigenicity of the paired cell lines was assessed in FoxN^{nu} mice, and the number of formed tumors per injection of each cell line is shown. GSEA of the paired cell lines with the most highly induced gene sets is shown (right).

(D–F) Glucose uptake (D), lactate levels (E), and oxygen consumption (F) were measured as relative amounts in each cell line, normalized to cell number. † $p < 0.0001$.

(G) ATP levels, normalized to cell number in BRAF(V600E)+vector and BRAF(V600E)+MITF treated with PLX4032 (1 μ M) for 24 hr.

*** $p < 0.001$ compared to control cells. Error bars represent SEM of at least three independent replicates.

See also Figure S4.

a large series of melanoma short-term cultures, but we have not observed an inverse correlation with glycolytic gene expression. We also found that MITF expression did not affect glucose uptake but decreased lactate production and increased oxygen consumption, consistent with a shift to oxidative metabolism. Thus, consistent with Warburg's initial hypothesis, the activation of glycolysis and the suppression of oxidative metabolism, as shown here to be initiated by oncogenic BRAF, are likely separate processes.

Overall, our data suggest that MITF is a major regulator of mitochondrial respiration in the melanocyte lineage by acting via PGC1 α . Tumors likely generate ATP via both glycolysis and oxidative phosphorylation (Colombi et al., 2011; Weinberg et al., 2010), and tumor cells may require mitochondria for functions other than ATP generation, such as fatty acid synthesis and glutaminolysis in some cases (Wise and Thompson, 2010; Dang, 2012). However, we show here that MITF-expressing melanomas have a higher level of oxidative gene expression. These data therefore suggest that MITF expression may serve as a biomarker for greater dependence on mitochondrial function. Because MITF has been difficult to drug directly (Haq and Fisher, 2011), the dependence of MITF-dependent melanoma

on oxidative phosphorylation thus presents a theoretical therapeutic approach. However, MITF paradoxically can promote tumorigenesis (e.g., Garraway et al., 2005; Yokoyama et al., 2011), whereas activation of MITF expression in normal melanocytes typically induces differentiation, which likely antagonizes tumorigenesis (D'Orazio et al., 2006; Carreira et al., 2006; Haq and Fisher, 2011). A rheostat model has been proposed to explain the apparent paradox of MITF (Goding, 2011), but definitive evidence of this model remains an area of active investigation. We show that BRAF inhibitors induce some, but not all, MITF target genes, implying that the context in which MITF is regulated may also contribute to its physiologic effects. Finally, it is also highly likely that MITF has protumorigenic effects outside of its induction of OXPHOS, so that any antitumorigenic effect of inducing OXPHOS may well be countered by other protumorigenic effects. In the future, it will be of great interest to examine how MITF can coordinate its numerous downstream effects.

Eight patients treated with vemurafenib had induction of PGC1 α , but a larger sample size will therefore be needed to evaluate the diagnostic and predictive role of PGC1 α induction in response to BRAF inhibitors. Interestingly, mutations in PGC1 α have been detected in recent melanoma whole-genome




Figure 7. Effects of 2,4-DNP on Growth Melanoma Cells In Vitro and In Vivo

(A) Number of BRAF(V600E)+vector and BRAF(V600E)+MITF melanoma cells following treatment with 2,4-DNP with indicated dose for 72 hr.

(B and C) Levels of PGC1 α mRNA (B) and ATP (C) in melanoma cell lines treated with vemurafenib (1 μ M) for 24 hr.

(D and E) Effects of 2,4-DNP (50 μ g/ml, 24 hr) on ATP (D) and lactate levels (E) in indicated cell lines in vitro. * $p < 0.05$.

(F and G) Effect of 2,4-DNP (20 mg/kg/day) or vemurafenib (75 mg/kg/day) on murine xenografts of indicated cell line ($n = 7-8$ per group).

** $p < 0.01$ and *** $p < 0.001$ compared to vehicle group. Error bars represent SEM of at least three independent replicates.

See also Figure S5.

sequencing efforts (Prickett et al., 2009; Stark et al., 2012). Our data nonetheless suggest that dysregulation of PGC1 α may have profound effects on metabolism of melanoma cells and may contribute to oncogenesis in certain cases.

We found that BRAF mutant melanomas treated with PLX4720 are dependent on ATP generation by mitochondria. Our data suggest that inhibition of mitochondrial metabolism may be most effective as initial therapy because most patients that have relapsed following BRAF inhibitors have reactivation of the MAPK pathway, which we have shown correlates with a decreased level of MITF and PGC1 α . Although mitochondrial function would likely be difficult to target therapeutically in many cancer types, agents that exploit bioenergetic and metabolic alterations in mitochondria have been proposed by Fantin and Leder (2006). We find that mitochondrial uncouplers enhanced the efficacy of PLX4720 in BRAF mutant melanomas, but demonstration of the in vivo efficacy of this combination remains to be firmly established, which possibly will involve derivation of improved mitochondrial pharmacologic agents. Although available drugs have generally unfavorable pharmacologic properties, 2,4-DNP had been used extensively in diet pills (Cutting and Tainter, 1933), and over 100,000 people had been treated worldwide with the drug at the time of its discontinuation (Tainter et al., 1934). Cases of dangerous side effects such as fatal hyperthermia led to its official discontinuation by 1938. Given the toxicities of the drugs, further development of

alternative oxidative phosphorylation inhibitors should be considered. Despite the recent successes of BRAF inhibition in the clinical arena, recurrence rates remain high, and survival is only extended several months. Although further in vivo studies will be crucial, uncouplers such as DNP, or other inhibitors of oxidative phosphorylation may be an alternative approach to enhance the effect of BRAF inhibitors in patients with melanoma.

EXPERIMENTAL PROCEDURES

Gene Expression and Bioinformatics

Immortal melanocytes (pmel*) and their transformed counterparts, pmel* BRAF(V600E)-vector and pmel* BRAF(V600E)+MITF, were maintained as described by Garraway et al. (2005). Global gene expression analysis was carried out using HG-U133A microarrays (Affymetrix).

RNA Isolation, ChIP, and Quantitative Real-Time PCR

ChIP was performed in primary human melanocytes using previously described methods by Cui et al. (2007). Chromatin was immunoprecipitated using rabbit polyclonal anti-MITF, or normal rabbit IgG as a control. Results are normalized to input DNA.

Clinical Samples

All patients gave informed consent for tissue acquisition as per an IRB-approved protocol (Office for Human Research Studies, Dana-Farber/Harvard Cancer Center). Tumors were biopsied before treatment (day 0), at 10–14 days during treatment.




Figure 8. BRAF Inhibitors Enhance Dependence on Mitochondrial Metabolism

(A–C) Sensitivity of A375M (A), WM1575 (B), and UACC-257 (C) melanoma cells overexpressing PGC1 α to treatment with PLX4720 for 72 hr.

(D) Photograph of M14 cells treated with PLX4720 (5 μ M), CCCP (20 μ M), or the combination for 72 hr. Scale bar represents 100 μ m.

(E) Cell number following treatment with mitochondrial uncouplers oligomycin A (1 μ M), CCCP (5 μ M), or 2,4-DNP (200 μ g/ml). Cell number was estimated after 72 hr of treatment.

* $p < 0.05$ and *** $p < 0.001$ compared to control. Error bars represent SEM of at least three independent replicates.

See also Figure S6.

siRNA Delivery and Analysis

siRNAs SMARTpools (Dharmacon) were delivered using the lipidoid delivery agent C12-133-B as described by Li et al. (2012).

Promoter Assays and Luciferase Experiments

The murine PGC1 α promoter was obtained from Addgene. Mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Mutant promoters were verified by sequencing. UACC-62 cells were transfected with each promoter construct, pRL-CMV Renilla control, and a M-MITF overexpression vector. PLX4720 treatment was for 48 hr. Results reported are averages of at least three independent experiments, normalized for transfection efficiency using Renilla luciferase.

Xenograft Tumor Studies

All mouse experiments were done in accordance with Institutional Animal Care and Use Committee-approved animal protocols at Dana-Farber Cancer Institute as described in the Supplemental Experimental Procedures.

Electron Microscopy

Electron microscopy of UACC-62 melanoma cells treated with vehicle or PLX4720 (3 μ M, 72 hr) was performed at the PMB Microscopy Core as described in Supplemental Experimental Procedures.

ACCESSION NUMBERS

Expression array data are deposited under GEO accession GSE38007.

SUPPLEMENTAL INFORMATION

Supplemental Information includes three tables, six figures, and Supplemental Experimental Procedures and can be found with this article online at <http://dx.doi.org/10.1016/j.ccr.2013.02.003>.

ACKNOWLEDGMENTS

We thank A. Winant for assistance with manuscript writing, M. McKee for electron microscopy, and A. Saur at the Luria Family Imaging Center (Dana-Farber Cancer Institute) for assistance with mouse xenograft experiments. This work was supported by the American Skin Association (to R.H.), NIAMS/NIH (R01 AR043369-16), Melanoma Research Alliance, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to D.E.F.), and The National Cancer Institute (R01CA163336 to J.S.S. and P50CA093683 to H.R.W.).

Received: May 21, 2012

Revised: November 27, 2012

Accepted: February 5, 2013

Published: March 7, 2013

REFERENCES

Arany, Z., Foo, S.Y., Ma, Y., Ruas, J.L., Bommi-Reddy, A., Girmun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S.M., et al. (2008). HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 α . *Nature* 451, 1008–1012.

- Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N.C., Nakano, K., Bartrons, R., Gottlieb, E., and Vousden, K.H. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell* 126, 107–120.
- Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d'Hayer, B., Mohamdi, H., Remenieras, A., et al.; French Familial Melanoma Study Group. (2011). A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* 480, 94–98.
- Bhalla, K., Hwang, B.J., Dewi, R.E., Ou, L., Twaddell, W., Fang, H.B., Vafai, S.B., Vazquez, F., Puigserver, P., Boros, L., and Girmun, G.D. (2011). PGC1 α promotes tumor growth by inducing gene expression programs supporting lipogenesis. *Cancer Res.* 71, 6888–6898.
- Board, R.E., Ellison, G., Orr, M.C.M., Kemsley, K.R., McWalter, G., Blockley, L.Y., Dearden, S.P., Morris, C., Ranson, M., Cantarini, M.V., et al. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. *Br. J. Cancer* 101, 1724–1730.
- Bogunovic, D., O'Neill, D.W., Belitskaya-Levy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R., Shapiro, R., Pavlick, A.C., et al. (2009). Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. *Proc. Natl. Acad. Sci. USA* 106, 20429–20434.
- Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 467, 596–599.
- Boni, A., Cogdill, A.P., Dang, P., Udayakumar, D., Njauw, C.N.J., Sloss, C.M., Ferrone, C.R., Flaherty, K.T., Lawrence, D.P., Fisher, D.E., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. *Cancer Res.* 70, 5213–5219.
- Bonnet, S., Archer, S.L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C.T., Lopaschuk, G.D., Puttagunta, L., Bonnet, S., et al. (2007). A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. *Cancer Cell* 11, 37–51.
- Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K.S., Testori, A., Larue, L., and Goding, C.R. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes Dev.* 20, 3426–3439.
- Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al.; BRIM-3 Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N. Engl. J. Med.* 364, 2507–2516.
- Chinsomboon, J., Ruas, J., Gupta, R.K., Thom, R., Shoag, J., Rowe, G.C., Sawada, N., Raghuram, S., and Arany, Z. (2009). The transcriptional coactivator PGC-1 α mediates exercise-induced angiogenesis in skeletal muscle. *Proc. Natl. Acad. Sci. USA* 106, 21401–21406.
- Colombi, M., Molle, K.D., Benjamin, D., Rattenbacher-Kiser, K., Schaefer, C., Betz, C., Thiemeier, A., Regenass, U., Hall, M.N., and Moroni, C. (2011). Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 activation. *Oncogene* 30, 1551–1565.
- Cui, R., Widlund, H.R., Feige, E., Lin, J.Y., Wilensky, D.L., Igras, V.E., D'Orazio, J., Fung, C.Y., Schanbacher, C.F., Granter, S.R., and Fisher, D.E. (2007). Central role of p53 in the suntan response and pathologic hyperpigmentation. *Cell* 128, 853–864.
- Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.B., LeBoit, P.E., et al. (2005). Distinct sets of genetic alterations in melanoma. *N. Engl. J. Med.* 353, 2135–2147.
- Cutting, W.C., and Tainter, M.L. (1933). Metabolic actions of dinitrophenol with the use of balanced and unbalanced diets. *J. Am. Med. Assoc.* 101, 2099–2012.
- Dang, C.V. (2012). Links between metabolism and cancer. *Genes Dev.* 26, 877–890.
- Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E., Jr., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat. Genet.* 41, 544–552.
- Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. (2002). Mutations of the BRAF gene in human cancer. *Nature* 417, 949–954.
- Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., and Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. *Cancer Cell* 15, 294–303.
- D'Orazio, J.A., Nobuhisa, T., Cui, R., Arya, M., Spry, M., Wakamatsu, K., Igras, V., Kunisada, T., Granter, S.R., Nishimura, E.K., et al. (2006). Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. *Nature* 443, 340–344.
- Eichner, L.J., Perry, M.-C., Dufour, C.R., Bertos, N., Park, M., St-Pierre, J., and Giguère, V. (2010). miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1 β /ERR γ transcriptional pathway. *Cell Metab.* 12, 352–361.
- Fantin, V.R., and Leder, P. (2006). Mitochondriotoxic compounds for cancer therapy. *Oncogene* 25, 4787–4797.
- Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. *Cancer Cell* 9, 425–434.
- Finck, B.N., and Kelly, D.P. (2006). PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. *J. Clin. Invest.* 116, 615–622.
- Flaherty, K.T., Puzanov, I., Kim, K.B., Ribas, A., McArthur, G.A., Sosman, J.A., O'Dwyer, P.J., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P.B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. *N. Engl. J. Med.* 363, 809–819.
- Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhi, R., Milner, D.A., Granter, S.R., Du, J., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 436, 117–122.
- Girmun, G.D. (2012). The diverse role of the PPAR γ coactivator 1 family of transcriptional coactivators in cancer. *Semin. Cell Dev. Biol.* 23, 381–388.
- Goding, C.R. (2011). Commentary. A picture of Mitf in melanoma immortality. *Oncogene* 30, 2304–2306.
- Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. *Nature* 445, 851–857.
- Greger, J.G., Eastman, S.D., Zhang, V., Bleam, M.R., Hughes, A.M., Smitheman, K.N., Dickerson, S.H., Laquerre, S.G., Liu, L., and Gilmer, T.M. (2012). Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. *Mol. Cancer Ther.* 11, 909–920.
- Handschin, C. (2009). The biology of PGC-1 α and its therapeutic potential. *Trends Pharmacol. Sci.* 30, 322–329.
- Handschin, C., Rhee, J., Lin, J., Tarr, P.T., and Spiegelman, B.M. (2003). An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1 α expression in muscle. *Proc. Natl. Acad. Sci. USA* 100, 7111–7116.
- Haq, R., and Fisher, D.E. (2011). Biology and clinical relevance of the microphthalmia family of transcription factors in human cancer. *J. Clin. Oncol.* 29, 3474–3482.
- Hemesath, T.J., Price, E.R., Takemoto, C., Badalian, T., and Fisher, D.E. (1998). MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. *Nature* 391, 298–301.
- Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001). CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. *Nature* 413, 179–183.
- Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., and Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. *Cancer Res.* 63, 5198–5202.

- Hoeflich, K.P., Gray, D.C., Eby, M.T., Tien, J.Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M.J., Stern, H.M., et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. *Cancer Res.* 66, 999–1006.
- Hoek, K.S., Schlegel, N.C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B.L., Nathanson, K.L., Phillips, D.J., Herlyn, M., et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell Res.* 19, 290–302.
- Joseph, E.W., Pratilas, C.A., Poulikakos, P.I., Tadi, M., Wang, W., Taylor, B.S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. *Proc. Natl. Acad. Sci. USA* 107, 14903–14908.
- Karasarides, M., Chilioches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C.J., et al. (2004). B-Raf is a therapeutic target in melanoma. *Oncogene* 23, 6292–6298.
- Kelly, D.P., and Scarpulla, R.C. (2004). Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev.* 18, 357–368.
- Klimcakova, E., Chénard, V., McGuirk, S., Germain, D., Avizonis, D., Muller, W.J., and St-Pierre, J. (2012). PGC-1 α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. *Cancer Res.* 72, 1538–1546.
- Lehman, J.J., Barger, P.M., Kovacs, A., Saffitz, J.E., Medeiros, D.M., and Kelly, D.P. (2000). Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. *J. Clin. Invest.* 106, 847–856.
- Leone, T.C., and Kelly, D.P. (2011). Transcriptional control of cardiac fuel metabolism and mitochondrial function. *Cold Spring Harb. Symp. Quant. Biol.* 76, 175–182.
- Li, J., Song, J.S., Bell, R.J.A., Tran, T.-N.T., Haq, R., Liu, H., Love, K.T., Langer, R., Anderson, D.G., Larue, L., and Fisher, D.E. (2012). YY1 regulates melanocyte development and function by cooperating with MITF. *PLoS Genet.* 8, e1002688.
- Lin, J., Wu, H., Tarr, P.T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani, E., Olson, E.N., et al. (2002). Transcriptional co-activator PGC-1 α drives the formation of slow-twitch muscle fibres. *Nature* 418, 797–801.
- Lin, J., Handschin, C., and Spiegelman, B.M. (2005a). Metabolic control through the PGC-1 family of transcription coactivators. *Cell Metab.* 1, 361–370.
- Lin, J., Yang, R., Tarr, P.T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005b). Hyperlipidemic effects of dietary saturated fats mediated through PGC-1 β coactivation of SREBP. *Cell* 120, 261–273.
- Lin, W.M., Baker, A.C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J.M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res.* 68, 664–673.
- Matoba, S., Kang, J.G., Patino, W.D., Wragg, A., Boehm, M., Gavrilo, O., Hurley, P.J., Bunz, F., and Hwang, P.M. (2006). p53 regulates mitochondrial respiration. *Science* 312, 1650–1653.
- Miura, S., Kai, Y., Kamei, Y., and Ezaki, O. (2008). Isoform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC-1 α) mRNA in response to beta2-adrenergic receptor activation and exercise. *Endocrinology* 149, 4527–4533.
- Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehár, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003). PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34, 267–273.
- Poulikakos, P.I., and Rosen, N. (2011). Mutant BRAF melanomas—dependence and resistance. *Cancer Cell* 19, 11–15.
- Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc. Natl. Acad. Sci. USA* 106, 4519–4524.
- Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R., Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y. (2009). Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4. *Nat. Genet.* 41, 1127–1132.
- Sahin, E., Colla, S., Liesa, M., Moslehi, J., Müller, F.L., Guo, M., Cooper, M., Kotton, D., Fabian, A.J., Walkey, C., et al. (2011). Telomere dysfunction induces metabolic and mitochondrial compromise. *Nature* 470, 359–365.
- Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N. Engl. J. Med.* 366, 707–714.
- Stark, M.S., Woods, S.L., Gartside, M.G., Bonazzi, V.F., Dutton-Regester, K., Aoude, L.G., Chow, D., Sereduk, C., Niemi, N.M., Tang, N., et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. *Nat. Genet.* 44, 165–169.
- Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J., Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature* 487, 500–504.
- Tainter, M.L., Cutting, W.C., and Stockton, A.B. (1934). Use of dinitrophenol in nutritional disorders: a critical survey of clinical results. *Am. J. Public Health Nations Health* 24, 1045–1053.
- Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N.K., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. *Proc. Natl. Acad. Sci. USA* 105, 3041–3046.
- Uldry, M., Yang, W., St-Pierre, J., Lin, J., Seale, P., and Spiegelman, B.M. (2006). Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. *Cell Metab.* 3, 333–341.
- Vachtenheim, J., and Borovanský, J. (2010). “Transcription physiology” of pigment formation in melanocytes: central role of MITF. *Exp. Dermatol.* 19, 617–627.
- Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 324, 1029–1033.
- Wan, P.T.C., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M., Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., and Marais, R.; Cancer Genome Project. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-Raf. *Cell* 116, 855–867.
- Wang, X., and Moraes, C.T. (2011). Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels. *Mol. Oncol.* 5, 399–409.
- Warburg, O. (1956). On the origin of cancer cells. *Science* 123, 309–314.
- Weinberg, F., Hamanaka, R., Wheaton, W.W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G.M., Budinger, G.R.S., and Chandel, N.S. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc. Natl. Acad. Sci. USA* 107, 8788–8793.
- Wellbrock, C., and Marais, R. (2005). Elevated expression of MITF counteracts B-Raf-stimulated melanocyte and melanoma cell proliferation. *J. Cell Biol.* 170, 703–708.
- Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., and Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. *PLoS One* 3, e2734.
- Wise, D.R., and Thompson, C.B. (2010). Glutamine addiction: a new therapeutic target in cancer. *Trends Biochem. Sci.* 35, 427–433.
- Wolfrum, C., and Stoffel, M. (2006). Coactivation of Foxa2 through Pgc-1 β promotes liver fatty acid oxidation and triglyceride/VLDL secretion. *Cell Metab.* 3, 99–110.
- Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C., and Spiegelman, B.M. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* 98, 115–124.

Wu, M., Hemesath, T.J., Takemoto, C.M., Horstmann, M.A., Wells, A.G., Price, E.R., Fisher, D.Z., and Fisher, D.E. (2000). c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mitf. *Genes Dev.* 14, 301–312.

Yokoyama, S., Woods, S.L., Boyle, G.M., Aoude, L.G., MacGregor, S., Zismann, V., Gartside, M., Cust, A.E., Haq, R., Harland, M., et al. (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature* 480, 99–103.

Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K., et al. (2001). Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature* 413, 131–138.

Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J.K., Markowitz, S., Zhou, S., et al. (2009). Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 325, 1555–1559.